GlaxoSmithKline Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Bhushan Akshikar
Chief executive officer
₹66.9m
Total compensation
| CEO salary percentage | 21.71% |
| CEO tenure | 2.4yrs |
| CEO ownership | n/a |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Earnings Update: Here's Why Analysts Just Lifted Their GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Price Target To ₹3,072
May 16
Earnings Not Telling The Story For GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) After Shares Rise 25%
Mar 13GlaxoSmithKline Pharmaceuticals Limited Just Recorded A 8.7% Revenue Beat: Here's What Analysts Think
Feb 19Subdued Growth No Barrier To GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Price
Jan 22GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | ₹9b |
| Dec 31 2024 | n/a | n/a | ₹9b |
| Sep 30 2024 | n/a | n/a | ₹7b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹15m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹34m | ₹4m | ₹6b |
Compensation vs Market: Bhushan's total compensation ($USD781.89K) is about average for companies of similar size in the Indian market ($USD760.25K).
Compensation vs Earnings: Bhushan's compensation has increased by more than 20% in the past year.
CEO
Bhushan Akshikar
2.4yrs
Tenure
₹66,885,000
Compensation
Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | 2.4yrs | ₹66.89m | no data | |
| Whole-Time Director & CFO | 3.1yrs | ₹68.92m | no data | |
| Executive Vice President of Human Resources | 4.4yrs | ₹37.40m | no data | |
| Vice President of Technology | 1.3yrs | no data | no data | |
| VP of Administration & Real Estate and Company Secretary | no data | ₹11.57m | no data | |
| Executive Vice President of Legal | 3.3yrs | no data | no data | |
| Vice President of Ethics & Compliance | 2.3yrs | no data | no data | |
| Executive Vice President of Communications & Government Affairs | less than a year | no data | no data | |
| Head of Growth Emerging Market | no data | no data | no data | |
| Commercial Head - Paediatric Vaccines | 2.3yrs | no data | no data | |
| Commercial Head of Adult Vaccines | 1.5yrs | no data | no data | |
| Executive VP & Country Head of Medical Affairs | less than a year | no data | no data |
2.3yrs
Average Tenure
Experienced Management: GLAXO's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹66.89m | no data | |
| Whole-Time Director & CFO | 3.1yrs | ₹68.92m | no data | |
| Non-Executive Chairperson | 6.1yrs | ₹3.25m | no data | |
| Independent Director | 3yrs | ₹2.65m | no data | |
| Non Executive Director | 8.1yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Non-Executive & Independent Director | 5yrs | ₹2.45m | no data |
3.1yrs
Average Tenure
62yo
Average Age
Experienced Board: GLAXO's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 19:43 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GlaxoSmithKline Pharmaceuticals Limited is covered by 24 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shirish Pardeshi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |
| Prakash Agarwal | Axis Capital Limited |